Compare · MDLN vs PODD
MDLN vs PODD
Side-by-side comparison of Medline Inc. (MDLN) and Insulet Corporation (PODD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and PODD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $45.62B, about 4.5x PODD ($10.09B).
- Over the past year, MDLN is down 14.9% and PODD is down 55.8% - MDLN leads by 40.9 points.
- Both names hit the wire about 12 times in the past 4 weeks.
- Both have 25 recent analyst ratings on file.
- Company
- Medline Inc.
- Insulet Corporation
- Price
- $34.68+1.26%
- $145.47-1.82%
- Market cap
- $45.62B
- $10.09B
- 1M return
- -10.57%
- -10.91%
- 1Y return
- -14.90%
- -55.81%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2007
- News (4w)
- 12
- 12
- Recent ratings
- 25
- 25
Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.
Latest MDLN
- SEC Form 4 filed by Chief Executive Officer Boyle James M
- SEC Form 4 filed by Chief Operating Officer Miller Stephen L
- Large owner Gic Private Ltd sold $57,280,000 worth of shares (1,600,000 units at $35.80) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $21,002,305 worth of shares (590,284 units at $35.58) (SEC Form 4)
- Large owner Mozart Holdco, Inc. converted options into 500,000 shares and disposed of 500,000 units of Class B Common Stock, increasing direct ownership by 81,083% to 233,520,656 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Medline Inc.
- Large owner Gic Private Ltd sold $79,971,448 worth of shares (2,248,612 units at $35.56) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Medline Inc.
- SEC Form 10-Q filed by Medline Inc.
Latest PODD
- President and CEO Mcevoy Ashley bought $162,217 worth of shares (1,100 units at $147.47), increasing direct ownership by 5% to 23,731 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Insulet Corporation
- Insulet downgraded by Truist with a new price target
- Insulet downgraded by Wells Fargo with a new price target
- Insulet downgraded by Analyst with a new price target
- Insulet downgraded by BTIG Research
- Insulet downgraded by Leerink Partners with a new price target
- SEC Form 10-Q filed by Insulet Corporation
- Insulet downgraded by Oppenheimer
- Insulet Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits